1. Donor-derived marrow mesenchymal stromal cell co-transplantation following a haploidentical hematopoietic stem cell transplantation trail to treat severe aplastic anemia in children.
- Author
-
Wang Z-, Yu H-, Cao F-, Liu Z-, Liu Z-, Feng W-, Liu X-, Yu Y-, Xiao Y, Li L-, and Zhou J
- Subjects
- Acute Disease, Adolescent, Allografts, Anemia, Aplastic blood, Child, Child, Preschool, Disease-Free Survival, Female, Graft vs Host Disease blood, Graft vs Host Disease mortality, Humans, Incidence, Male, Severity of Illness Index, Survival Rate, Transplantation Chimera blood, Anemia, Aplastic mortality, Anemia, Aplastic therapy, Hematopoietic Stem Cell Transplantation, Mesenchymal Stem Cell Transplantation, Tissue Donors
- Abstract
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is associated with an increased risk of graft failure and severe graft-versus-host disease (GVHD). Recent studies have shown that mesenchymal stromal cells (MSCs) display potent immunosuppressive effects and can support normal hematopoiesis. In a multi-center trial, we co-transplanted culture-expanded donor-derived bone marrow MSCs (BM-MSCs) into 35 children with severe aplastic anemia (SAA) undergoing haplo-HSCT. All 35 patients (100%) achieved hematopoietic reconstitution and showed sustained full donor chimerism. The median time for myeloid engraftment was 14 days (range 10-22 days), while that for platelet engraftment was 18 days (range 9-36 days). The incidence of grade II-IV acute GVHD and chronic GVHD was 25.71 and 22.86%, respectively. The overall survival rate was 85.71% with a median of 22 months (range 3.5-37 months). The combined transplantation of haploidentical HSCs and BM-MSCs into children with SAA without an HLA-identical sibling donor is relatively safe and may represent an effective new therapy to improve survival rates and reduce the risk of graft failure.
- Published
- 2019
- Full Text
- View/download PDF